Skip to main content
SpringerLink
Log in

Management of Respiratory Syncytial Virus Infections

  • Chapter
Antiviral Chemotherapy 4

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 394))

Abstract

Almost from the time of its discovery nearly 4 decades ago in chimpanzees and humans with respiratory infections, respiratory syncytial virus (RSV) was appreciated as a major cause of serious lower respiratory disease in young children.1 However, despite intensive research in many laboratories, epidemics of RSV continue to occur unchecked throughout the world. Although ribavirin has been used to treat RSV disease for over a decade, its efficacy and the indications for its administration remain controversial. However, recent studies suggest that immunotherapeutic and immunoprophylactic strategies may ultimately lead to control of RSV infections.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hall CB, McCarthy CA. “Respiratory syncytial virus”, Chapter 136 in Mandell GL, Bennett JE, Dolin R, Editors, Principles and Practice of Infectious Diseases, 4th Edition, Churchill Livingstone, New York 1995, p. 1501–18.

    Google Scholar 

  2. Englund JA, Sullivan CJ, Jordan MC, et al. Respiratory syncytial virus infection in immunocompromised adults. Ann Int Med 1988; 109: 203–208.

    Article  PubMed  CAS  Google Scholar 

  3. Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992; 165: 987–93.

    Article  PubMed  CAS  Google Scholar 

  4. Pohl C. Green M, Wald ER, et al. Respiratory syncytial virus infections in pediatric liver transplant recipients. J Infect Dis 1991; 165: 166–9.

    Article  Google Scholar 

  5. Hertz MI, Englund JA, Snover D, et al. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: A clinical approach and review of the literature. Medicine 1989; 68: 269–81.

    Article  PubMed  CAS  Google Scholar 

  6. Whimbey E, Couch R, Englund J, et al. Respiratory syncytial virus (RSV) pneumonia among hospitalized adult patients with leukemia. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 1994. Abstract H84.

    Google Scholar 

  7. King JC, Burke AR, Clemens JD, et al. Respiratory syncytial virus illnesses in human immunodeficiency virus-and noninfected children. Pediatr Infect Dis J 1993; 12: 733–9.

    Article  PubMed  Google Scholar 

  8. Chandwani S, Barkowsky W, Krasinski K, et al. Respiratory syncytial virus infection in human immunodeficiency virus-infected children. J Pediatr 1990; 117: 251–4.

    Article  PubMed  CAS  Google Scholar 

  9. Groothuis JR, Salbenblatt CK, Lauer BA. Severe respiratory syncytial virus infection in older children. Am J Dis Children 1990; 144: 348.

    Google Scholar 

  10. Mathur U, Bentley DW, Hall CB. Concurrent respiratory syncytial virus and influenza A infections in the instititutionalized elderly and chronically ill. Ann Int Med 1980; 93: 49–52.

    Article  PubMed  CAS  Google Scholar 

  11. Takimoto CH, Cram Dl, Root RK. Respiratory syncytial virus infections on an adult medical ward. Arch Intern Med 1991; 15: 706–8.

    Article  Google Scholar 

  12. Agius G, Dindinaud G, Biggar RJ, et al. An epidemic of respiratory syncytial virus in elderly people: Clinical and serological findings. J Med Virol 1990; 30: 117–27.

    Article  PubMed  CAS  Google Scholar 

  13. Guidry GG, Black-Payne CA, Payne DK, et al. Respiratory syncytial virus infection among intubated adults in a university medical intensive care unit. Chest 1991; 100: 1377–84.

    Article  PubMed  CAS  Google Scholar 

  14. Gilbert BE, Knight V. Overview of ribavirin, selenazole and derivatives. In Mills J, Corey L, editors, Antiviral Chemotherapy, New Directions for Clinical Application and Research. Elsevier, New York, 1986. p63–74.

    Google Scholar 

  15. Toltzis P. The mechanism of action of ribavirin. Ibid, 74–77.

    Google Scholar 

  16. McIntosh K. Chemotherapy of respiratory syncytial virus infections. Ibid, 83–88.

    Google Scholar 

  17. Hayden FG Update on antiviral chemotherapy of respiratory viral infections. In Mills J, Corey L, editors, Antiviral Chemotherapy, New Directions for Clinical Application and Research, vol 2. Elsevier, New York, 1989. p117–142.

    Google Scholar 

  18. Hayden FG. Antiviral agents (ribavirin). In Mandell GL, Bennett JE, Dolin R, Editors, Principles and Practice of Infectious Diseases, 4th Edition, Churchill Livingstone, New York 1995, p430–31.

    Google Scholar 

  19. Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983; 308: 1443–7.

    Article  PubMed  CAS  Google Scholar 

  20. Hall CB, McBride JT, Gala CL, et al. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA 1985; 254: 3047–3051.

    Article  PubMed  CAS  Google Scholar 

  21. Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991; 325: 24.

    Article  PubMed  CAS  Google Scholar 

  22. Meert KL, Sarnaik AP, Gelmini MJ, et al. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: A prospective, double-blind, randomized trial. Crit Care Med 1994; 22: 566.

    Article  PubMed  CAS  Google Scholar 

  23. England JA, Piedra PA, Ahn YM, et al. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Ped 1994; 125: 635–41.

    Article  Google Scholar 

  24. Wheeler JG, Wofford J, Turner MS, et al. Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection. Pediatr Infect Dis J 1993; 12: 209–13.

    Article  PubMed  CAS  Google Scholar 

  25. Treanor JJ. Viral infections of the respiratory tract: prevention and treatment. Int J Antimicrob Agents 1994; 4: 1–22.

    Article  PubMed  CAS  Google Scholar 

  26. Chipps BE, Sullivan WF, Portnoy JM. Alpha-2A-interferon for treatment of bronchiolitis by respiratory syncytial virus. Pediatr Infect Dis J 1993; 12: 663–8.

    Google Scholar 

  27. Groothuis JR, Simoes EAF. Immunoprophylaxis and immunotherapy: role in the prevention and treatment of respiratory syncytial virus. Int J Antimicrob Agents 1993; 2: 97–104.

    Article  PubMed  CAS  Google Scholar 

  28. Rimensburger PC, Schaad UB. Clinical experience with aerosolized immunoglobulin treatment of RSV infection in infants. Pediatr Inf Dis 1994; 13: 328–30.

    Article  Google Scholar 

  29. Englund JA. Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody. [Review]. Pediatr Infect Dis J 1994; 13: 449–53.

    Article  PubMed  CAS  Google Scholar 

  30. Garcia O, Martin M, Dopazo J, et al. Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein. J Virol 1994; 68: 5448–5459.

    PubMed  CAS  Google Scholar 

  31. Taylor G, Stott EJ, Bew M, et al. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunol 1984; 52: 137.

    CAS  Google Scholar 

  32. Walsh EE, Schlesinger JJ, Brandriss MW, et al. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun 1984; 43: 756–758.

    PubMed  CAS  Google Scholar 

  33. Chanock RM, Parrott RH, Connors M, et al. Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. Pediatr 1992; 90: 137.

    CAS  Google Scholar 

  34. Hall CB. Prospects for a respiratory syncytial virus vaccine. [Review]. Science 1994; 265: 1393.

    Article  PubMed  CAS  Google Scholar 

  35. Hall CB, Walsh EE, Long CE,et al. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991; 163: 693–8.

    Article  PubMed  CAS  Google Scholar 

  36. Lamprecht CL, Krause HE, Mufson MA. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis 1976; 134: 211.

    Article  PubMed  CAS  Google Scholar 

  37. Levin MJ. Treatment and prevention options for respiratory sync, virus infections. J Pediatr 1994; 124: 522 - S27.

    Google Scholar 

  38. Piazza FM, Johnson SA, Ottolini MG, et al. Lmmunotherapy of respiratory syncytial virus infection in cotton rats (Sigmodon fulviventer) using IgG in a small-particle aerosol. J Infect Dis 1992; 166: 1422–4.

    Article  PubMed  CAS  Google Scholar 

  39. Prince GA, Hemming VG, Horswood RL, et al. Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J Virol 1987; 61: 1851–1854.

    PubMed  CAS  Google Scholar 

  40. Crowe JE, Murphy BR, Chanock RM, et al. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci 1994; 91: 1386–1390

    Article  PubMed  CAS  Google Scholar 

  41. Weltzin R, Hsu SA, Mittlev ES, et al. Intranasal IgA against RSV protects against upper and lower respiratory tract infections in mice. Antimicrob Ag Chemother 1994; 38: 2785–91.

    Article  CAS  Google Scholar 

  42. Hemming VG, Rodriguez W, Kim HW, et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young childrén. Antimicrob Ag Chemother 1987; 31: 1882–1886.

    Article  CAS  Google Scholar 

  43. Taylor G, Furze J. Tempest PR, et al. Humanised monoclonal antibody to respiratory syncytial virus. Lancet 1991; 337: 1411–1412.

    Article  PubMed  CAS  Google Scholar 

  44. Rimensberger PC, Schaad UB. Clinical experience with aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. Pediatr Infect Dis J 1994; 13: 328.

    Article  PubMed  CAS  Google Scholar 

  45. Siber GR, Leszcynski J, Pena CV. et al. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis 1992; 165: 456–63.

    Article  PubMed  CAS  Google Scholar 

  46. Meissner HC, Fulton DR, Groothuis J, et al. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Ag Chemother 1993; 37: 1655–8.

    Article  CAS  Google Scholar 

  47. Groothius JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993; 329: 1524–30.

    Article  Google Scholar 

  48. Murphy BR, Hall SL, Kulkarni AB, et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. [Review]_ Virus Res 1994; 32: 13.

    PubMed  CAS  Google Scholar 

  49. Oien, NL, Brideau RJ, Thomsen DR, et al. Vaccination with a heterologous respiratory syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity. Vaccine 1993; 11: 1040.

    Article  PubMed  CAS  Google Scholar 

  50. Crowe JEJ, Collins PL, London WT, et al. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 1993;11:1395–1404_

    Google Scholar 

  51. Crowe JJ, Bui PT, London WT, et al. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 1994; 12: 691.

    Article  PubMed  Google Scholar 

  52. Hsu KH, Lubeck MD, Bhat BM, et al. Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model. Vaccine 1994; 12: 607.

    Article  PubMed  CAS  Google Scholar 

  53. Kakut TJ, Soike K, Brideau RT, et al. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J Infect Dis 1993; 167: 553–61.

    Article  Google Scholar 

  54. Hildreth SW, Baggs RR, Brownstein DG, et al. Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at 3–6 months after immunization. Vaccine 1993; 11: 615.

    Article  PubMed  CAS  Google Scholar 

  55. Tristram DA, Welliver RC, Mahar CK, et al. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18–36 months old. J Infect Dis 1993; 167: 191–5.

    Article  PubMed  CAS  Google Scholar 

  56. Paradiso PR, Hildreth SW, Hogerman DA, et al. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Ped Infect Dis J 1994; 13: 792.

    Article  CAS  Google Scholar 

  57. Tristram DA, Welliver RC, Hogerman DA, et al. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement. Vaccine 1994; 12: 551.

    Article  PubMed  CAS  Google Scholar 

  58. Belshe RB, Anderson EL, Walsh EE. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 1993; 168: 1024–9.

    Article  PubMed  CAS  Google Scholar 

  59. Pringle CR, Filipiuk AH, Robinson BS, et al Immunogenicity and pathogenicity of a triple temperature-sensitive modifed respiratory syncytial virus in adult volunteers. Vaccine 1993; 11: 473–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. John Mills
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Macfarlane Burnet Centre for Medical Research, Fairfield, Victoria, Australia

    John Mills

  2. University of California San Francisco, San Francisco, USA

    Paul A. Volberding

  3. University of Washington, Seattle, Washington, USA

    Lawrence Corey

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer Science+Business Media New York

About this chapter

Cite this chapter

Mills, J. (1996). Management of Respiratory Syncytial Virus Infections. In: Mills, J., Volberding, P.A., Corey, L. (eds) Antiviral Chemotherapy 4. Advances in Experimental Medicine and Biology, vol 394. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9209-6_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-9209-6_17

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-9211-9

  • Online ISBN: 978-1-4757-9209-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation